| Literature DB >> 33914245 |
Abstract
Emerging contaminants such as pharmaceuticals, illicit drugs and personal care products can be released to the environment in untreated wastewater/stormwater mixtures following storm events. The frequency and intensity of combined sewer overflows (CSOs) has increased in some areas due to increasing urbanisation and climate change. Therefore, this review provides an up-to-date overview on CSOs as an environmental source of emerging contaminants. Other than compounds with high removal, those chiral species subject to enantioselective changes (i.e. degradation or inversion) during wastewater treatment can be effective markers of CSO discharge in the environment. A proposed framework for the selection of emerging contaminants as markers of CSOs is outlined. Studies have demonstrated that CSOs can be the main source of emerging contaminants with high removal efficiency during wastewater treatment (e.g. > 90%). However, the impact of CSOs on the environment is location specific and requires decision-making on their appropriate management at catchment level. This process would be aided by further studies on CSOs which incorporate the monitoring of emerging contaminants and their effects in the environment with those more routinely monitored pollutants (e.g. pathogens and priority substances). Mitigation and treatment strategies for emerging contaminants in CSOs are also discussed.Entities:
Keywords: Chiral; Combined sewer overflow; Emerging contaminant; Micropollutant; Pharmaceutical; Wastewater
Year: 2021 PMID: 33914245 PMCID: PMC8241663 DOI: 10.1007/s11356-021-14103-1
Source DB: PubMed Journal: Environ Sci Pollut Res Int ISSN: 0944-1344 Impact factor: 4.223
Fig. 1Separate sewer systems (a) and combined sewer systems (b) under ‘dry’ weather (left) and wet weather conditions (right). Key: WTP, wastewater treatment plant; CSO, combined sewer overflow
Concentration of emerging contaminants in combined sewer overflows
| Emerging contaminant | Family/use | Monitoring strategy | Mean concentration (ng L−1) | Ref. |
|---|---|---|---|---|
| Diclofenac | NSAID | Grab samples of five CSOs collected during intensive rainfall. Number of replicates range from one to seven (14 samples in total). Samples collected from Aire and Calder catchments, Yorkshire, UK | 74–388 | A |
| Erythromycin | Antibiotic | < 5–1603 | ||
| Ibuprofen | NSAID | 76–2734 | ||
| Mefenamic acid | NSAID | < 5–19 | ||
| Propranolol | Beta-blocker | < 5–11 | ||
| Ibuprofen | NSAID | Single grab sample of sewage overflow. Sample collected from Cooks River catchment, Sydney, Australia. | 244 | B |
| Naproxen | NSAID | 25 | ||
| Caffeine | Stimulant | Grab samples collected by automated sampler during CSO events at two locations. Eight and two CSO events captured (125 and 10 samples collected, respectively). Samples collected from sewer of Greater Montreal Area, Canada. | 270 and 3248 | C |
| Carbamazepine | Antiepilepsy | 184 and 4 | ||
| Paracetamol | Analgesic | 3591 | ||
| Theophylline | Stimulant | 2381 and 57 | ||
| Acesulfame | Sweetener | Volume-proportional samples collected during CSO events at one location (seven CSO events captured – 25 samples collected in total). Samples collected from WTP South-West of Stuttgart, Germany. | 2965 | D |
| Atenolol | Beta-blocker | 41 | ||
| Bezafibrate | Lipid-regulator | 90 | ||
| Caffeine | Stimulant | 9030 | ||
| Carbamazepine | Antiepilepsy | 84 | ||
| Diatrizoate | Contrast agent | 19 | ||
| Diclofenac | NSAID | 157 | ||
| Galaxolide | Musk | 184 | ||
| Ibuprofen | NSAID | 1239 | ||
| Iohexol | Contrast agent | 144 | ||
| Iomeprol | Contrast agent | 207 | ||
| Iopamidol | Contrast agent | 95 | ||
| Iopromide | Contrast agent | 212 | ||
| Metoprolol | Beta-blocker | 200 | ||
| Naproxen | NSAID | 118 | ||
| Propranolol | Beta-blocker | 9 | ||
| Sulfamethoxazole | Antibiotic | 23 | ||
| Sucralose | Sweetener | 752 | ||
| Tonalide | Musk | 31 | ||
| Triclosan | Antibacterial | 122 | ||
| Caffeine | Stimulant | Grab samples of two CSOs following 24.5 mm of rainfall over 11 hours following six days without rainfall. Samples collected from Jung-rang Creek area, South Korea. | 2149 | E |
| Iohexol | Contrast agent | 1165 | ||
| Iopamidol | Contrast agent | 2394 | ||
| Iopromide | Contrast agent | 940 | ||
| Carbamazepine | Antiepilepsy | Passive samplers deployed at three locations in Switzerland (10 events captured). | 49–170a | F |
| Clarithromycin | Antibiotic | 54–55a | ||
| Diclofenac | NSAID | 13–860a | ||
| Carbamazepine | Antiepilepsy | Passive samplers deployed at 20 locations in Switzerland (95 events captured). | 250–4800 | G |
| Diclofenac | NSAID | 78–1000 |
A, Kay et al. 2017; B, Khan et al. 2014; C, Madoux-Humery et al. 2013; D, Launay et al. 2016; E, Ryu et al. 2014; F, Mutzner et al. 2019; G, Mutzner et al. 2020 Key: CSO, combined sewer overflows; NA, not applicable; NSAID, nonsteroidal anti-inflammatory; -, not measured
aRange presented
Multicompound studies aimed at investigating the effect of combined sewer overflows on emerging contaminants in the environment
| Location | Sampling strategy | Target emerging contaminants for quantitative analysis | Analysis method | Findings | Ref. | |||
|---|---|---|---|---|---|---|---|---|
| Mode | Sites | Frequency | Separation | Detection | ||||
| River Thames estuary, UK. | Grab | 2 | Daily on weekdays over 6-weeks. Composite influent and effluent wastewater samples also sampled to identify potential CSO markers. | Amitriptyline, antipyrine, bezafibrate, benzoylecgonine, caffeine, carbamazepine, chloramphenicol, clofibric acid, cocaine, dextromethorphan, diazepam, diclofenac, fluoxetine, furosemide, ketamine, ketoprofen, MDMA, mephedrone, metoprolol, nifedipine, nimesulide, nortriptyline, propranolol, sulfamethoxazole, sulfamethazine, sulfaphenazole, sulfapyridine, temazepam, tramadol, trimethoprim, warfarin. | UPLC C18 | Orbitrap HRMS | Short-term increase of caffeine, cocaine and benzoylecgonine concentration (within an order of magnitude) following CSO events. | A |
| Aire and Calder catchments, UK. | Grab | 7 | Monthly over 18-months. Included sampling of wastewater effluents and two CSO discharges. | Diclofenac, erythromycin, ibuprofen, mefenamic acid, propranolol. | HPLC C18 | Q-TOF MS/MS | Variability in concentrations observed but no correlation made to rainfall or CSO events. | B |
| Körsch catchment, Germany. | Grab | 5 | Nine samples collected during dry weather and following four CSO discharges. Influent wastewater and CSO discharges also sampled using composite samplers. | Acesulfame, atenolol, bezafibrate, caffeine, carbamazepine, diatrizoate, diclofenac, galaxolide, ibuprofen, iohexol, iomeprol, iopamidol, iopromide, metoprolol, naproxen, propranolol, sulfamethoxazole, sucralose, tonalide, triclosan. | HPLC | LIT MS/MS | Diclofenac exceeded its AA-EQS (100 ng L−1) downstream of the CSO discharge (but upstream of the WTP effluent discharge) during wet weather in 25% of samples. The AA-EQS was not exceeded during dry weather. Diclofenac concentrations downstream of the CSO and WTP effluent discharges were lower during wet weather. However, all samples here exceeded the AA-EQS. | C |
| Jung-rang creek, South Korea. | Grab | 5 | Once during dry weather and wet weather conditions. Wet weather samples collected following 24.5 mm of rainfall during 11 h after 6 days without rainfall. | Acesulfame, atenolol, benzophenone, caffeine, carbamazepine, diclofenac, diltiazem, diphenhydramine, estrone, ibuprofen, iohexol, iopamidol, iopromide, gemfibrozil, meprobamate, naproxen, primidone, propylparaben, sucralose, sulfamethoxazole, triclocarban, triclosan. | UPLC C18 | QQQ | 34%a lower cumulative concentration under wet weather conditions. However, individual compound concentrations not reported. | D |
| WTP, Burlington, US. | 24h flow-weighted composites | 3 | Influent ( | 3β-coprostanol, 11-ketotestosterone, 17β-estradiol, β-sitosterol, androstenedione, benzophenone, bisphenol-A, caffeine, cholesterol, | GC low polarity proprietary phase | QQQ | CSO represent 10% of wastewater discharges but account for 40-90% of released loads of emerging contaminant with > 90% WTP removal. | E |
| Jamaica Bay, US. | Grab | 24 | Maximum of three times during dry weather conditions. Seven further samples collected from various locations following storm. | Antipyrine, caffeine, carbamazepine, cimetidine, codeine, cotinine, diltiazem, fenofibrate, fluoxetine, hydrocodone, ketoprofen, metformin, nicotine, nifedipine, paracetamol, paraxanthine, ranitidine, salbutamol, sulfamethoxazole, trimethoprim, warfarin. | HPLC C18 | Q-TOF MS/MS | Following the storm event, concentrations of nicotine and paracetamol were similar or greater than dry weather concentrations. | F |
A, Munro et al. 2019; B, Kay et al. 2017; C, Launay et al. 2016; D, Ryu et al. 2014; E, Phillips et al. 2012; F, Benotti and Brownawell 2007
Key: CSO, combined sewer overflows; HPLC, high performance liquid chromatography; HRMS, LIT MS/MS, linear ion trap mass spectrometer; high-resolution mass spectrometry; MDMA, 3,4-methylenedioxymethamphetamine; QQQ, triple-quadrupole mass spectrometer; Q-TOF MS/MS, quadrupole-time of flight mass spectrometer; UPLC, ultra-performance liquid chromatography
aCummulative concentration includes several pesticides and flame retardant
Emerging contaminants proposed as markers of untreated wastewater
| Emerging contaminant | Family/use | Reasoning | Evidence in the environment | Ref. | Literature wastewater data | ||||
|---|---|---|---|---|---|---|---|---|---|
| Untreated wastewater concentration (ng L−1) | Treatment removal (%) | Untreated wastewater EF | Treated wastewater EF | Ref. | |||||
| Caffeine | Stimulant | High removal during wastewater treatment and low concentration variation High removal during wastewater treatment High removal during wastewater treatment High removal during wastewater treatment | Elevated concentrations following CSO events | A | 1045–150,414 | > 95 | NA | NA | H |
| 3400–6600 | > 99 | NA | NA | I | |||||
| B | 7000–73,000 | 81 to > 99 | NA | NA | J | ||||
| Caffeine loads in stream correlated with rainfall | C | 42,400–43,800 | > 99 | NA | NA | K | |||
| 5250–9310 | > 99 | NA | NA | L | |||||
| D | 42,000 | 64 | NA | NA | E | ||||
Elevated concentration at site of untreated wastewater discharge Elevated concentrations following CSO events | 5094–1,214,375 | > 99 | NA | NA | M | ||||
| 74,813 | 92 | NA | NA | N | |||||
| 135,883–184,819 | - | NA | NA | O | |||||
| Theophylline | Bronchodilator | High removal during wastewater treatment | Elevated concentrations following CSO events | D | 1745–107,915 | > 93 | NA | NA | H |
| 146,500 | 95 | NA | NA | N | |||||
| 16,765–237,345 | 99 | NA | NA | M | |||||
| 75,413–137,196 | - | NA | NA | O | |||||
| Nicotine | Stimulant | High removal during wastewater treatment | No decrease in environmental concentration following CSO event. | E | 17,000 | 87 | NA | NA | E |
| 87–9086 | > 95 | NA | NA | H | |||||
| 50–89,600 | 65 to 99 | NA | NA | P | |||||
| 4874–11,866 | 99 | NA | NA | M | |||||
| 7750 | 98 | NA | NA | N | |||||
| 3340–8562 | - | NA | NA | O | |||||
| Cotinine | Stimulant metabolite | High removal during wastewater treatment | Elevated concentration at site of untreated wastewater discharge | C | 1972 | 82 | NA | NA | N |
| 1882–2437 | - | NA | NA | O | |||||
| 44–66 | > 69 | NA | NA | H | |||||
| 780–2880 | 91 to 99 | NA | NA | J | |||||
| 3333–4892 | > 99 | NA | NA | M | |||||
| Paracetamol | Analgesic | High removal during wastewater treatment High removal during wastewater treatment High removal during wastewater treatment | No decrease in concentration following CSO event. Elevated concentration at site of untreated wastewater discharge Elevated concentrations following CSO events | E | 61,000 | 99 | NA | NA | E |
| 68,107–482,687 | ≥ 92 | NA | NA | Q | |||||
| C | 7100–11,400 | > 99 | NA | NA | R | ||||
| - | > 90 | NA | NA | S | |||||
| D | 136,887–343,620 | > 99 | NA | NA | M | ||||
| 138,164 | 99 | NA | NA | N | |||||
| Ibuprofen | NSAID | EF change during wastewater treatment. | Surface water EFs were in the range of sewage overflows. | F | - | - | 0.73 | 0.50 | F |
| 9055–15,780 | 95 | - | - | M | |||||
| 968–6328 | > 85 | - | - | Q | |||||
| 990–3300 | > 95 | 0.85–0.89 | 0.47–0.67 | T | |||||
| 1213–2058 | - | 0.79–0.86 | 0.63–0.68 | U | |||||
| - | 17 to 99 | 0.73–0.90 | 0.60–0.76 | V | |||||
| 12,907 | 90 | - | - | N | |||||
| Naproxen | NSAID | EF change during wastewater treatment due to chiral inversion. | Surface water EFs were in the range of sewage overflows. | F | - | - | > 0.96 | 0.65–0.92 | F |
| 2925–5455 | 47 | - | - | M | |||||
| 400–3504 | > 57 | - | - | Q | |||||
| 30–430 | - | > 0.99 | 0.88–0.91 | W | |||||
| 1067–3202 | - | 0.98–0.99 | 0.93–0.96 | U | |||||
| - | 24 to 89 | 0.88–0.90 | 0.71–0.86 | V | |||||
| 13,660 | 74 | - | - | N | |||||
| Cocaine | Stimulant | High removal during wastewater treatment and low concentration variation | Elevated environmental concentrations following CSO events. | A | 882–1575 | > 99 | NA | NA | A |
| 21–1837 | 25 to ≥ 99 | NA | NA | Q | |||||
| 5–209 | 37 to 91 | NA | NA | H | |||||
| 92–753 | 93 to > 99 | NA | NA | X | |||||
| 195–961 | 96 | NA | NA | Y | |||||
| 430 | 83 | NA | NA | N | |||||
| 397–694 | - | NA | NA | O | |||||
| Benzoylecgonine | Stimulant metabolite | High removal during wastewater treatment and low concentration variation | Elevated environmental concentrations following CSO events. | A | 1973–2544 | > 98 | NA | NA | A |
| 126–3715 | No removal to ≥ 99 | NA | NA | Q | |||||
| 16–567 | 27 to 81 | NA | NA | H | |||||
| 322–2258 | 93 to 99 | NA | NA | X | |||||
| 545–3790 | 88 | NA | NA | Y | |||||
| 1247 | 69 | NA | NA | N | |||||
| 754–1604 | - | NA | NA | O | |||||
| Amphetamine | Stimulant | High removal and change in EF during wastewater treatment. | Elevated concentration at site of untreated wastewater discharge with EF value (0.43) typical of untreated UK wastewater | C | 255–12,020 | ≥ 95 | - | - | Q |
| 64–368 | > 99 | 0.32–0.46 | - | Z | |||||
| 3–3113 | ≥ 89 | 0.16–0.44 | 0.00–0.29 | AA | |||||
| 291–412 | - | 0.41–0.43 | - | O | |||||
| 17–3113 | ≥ 89 | - | - | H | |||||
| 288 | 77 | - | - | N | |||||
| Propranolol | Beta-blocker | Change in EF during wastewater treatment | EF values in surface waters with untreated wastewater discharges were similar to EF values in untreated wastewater. | G | 13–250 | - | 0.49–0.54 | 0.30–0.44 | G |
| 54–100 | 28 | - | - | A | |||||
| 110–1962 | No removal to 35 | - | - | Q | |||||
| 108–1130 | 59 to 78 | - | - | R | |||||
| 122 | 5 | - | - | N | |||||
| 28–56 | No removal to 34 | 0.37–0.46 | 0.39–0.45 | AB | |||||
A, Munro et al. 2019; B, Buerge et al. 2003; C, Ramage et al. 2019; D, Poopipattana et al. 2021; E, Benotti and Brownawell 2007; F, Khan et al. 2014; G, Fono and Sedlak 2005; H, Baker and Kasprzyk-Hordern 2013; I, Sui et al. 2010; J, Buerge et al. 2006; K, Thomas and Foster 2005; L, Froehner et al. 2011; M, Archer et al. 2017; N, Petrie et al. 2016; O, Castrignanò et al. 2016; P, Ekpeghere et al. 2018; Q, Kasprzyk-Hordern et al. 2009; R, Radjenović et al. 2009; S, Matsuo et al. 2011; T, Buser et al. 1999; U, Caballo et al., 2015; V, Matamoros et al. 2009; W, Suzuki et al. 2014; X, van Nuijs et al. 2009; Y, Postigo et al. 2010; Z, Kasprzyk-Hordern et al. 2010; AA, Kasprzyk-Hordern and Baker 2012; AB, López-Serna et al. 2013
Key: NSAID, nonsteroidal anti-inflammatory; EF, enantiomeric fraction; NA, not applicable; -, not measured; CSO, combined sewer overflow; SO, sewage overflow
Fig. 2Proposed framework for the selection of emerging contaminants as markers of combined sewer overflows. Key: EF, enantiomeric fraction; CSO, combined sewer overflow
Fig. 3Occurrence of cocaine, benzoylecgonine and caffeine in the River Thames during November–December 2014. Bars represent mean concentration from two replicates and whiskers represent the maximum concentration measured. Key: +, storm water and untreated wastewater were combined and released directly into river; *, storm water and treated wastewater were combined and released into environment (reproduced from Munro et al. 2019)